Last week I showed you the destination.

A £100M exit with 40%+ founder ownership. £24-36M in your pocket after UK capital gains tax. No retail required. Built in five years or fewer from the UK.

The EBITDA math is real. The Hiya Health proof case is real. The exit opportunity is real.

But a destination without a route is just a daydream.

This issue is the route.

Every section below maps directly to a phase of the RULE OF ONE™ framework — the operating system I install with subscription-first CPG and wellness founders who are serious about building to exit with clean economics and real ownership intact.

This is not a motivational framework. It is an engineering blueprint. Follow it in sequence and the £100M exit is not a hope. It is a mathematical outcome.

There is one thing no framework fixes.

A mediocre product with a world-class operating system produces a mediocre outcome. Every section below assumes you have already done the hard work of building something worth subscribing to.

That means understanding the difference between cultural wellness and prescriptive positioning.

Cultural wellness brands — the feel-good drinks, the lifestyle supplements, the products you have when you feel like it — live in a low-commitment psychological category. Customers use them when motivated. They cancel when life gets busy. Retention curves collapse in month two and never recover.

Prescriptive products live in a different category entirely. They feel like a medical protocol. The subscriber does not skip them. They become as non-negotiable as a morning routine, a medication, a daily commitment. That psychological positioning is worth more than any retention email you will ever write.

The brands that hit 50%+ retention at month twelve are almost always prescriptive by design. High-specificity health problem. Science-backed formulation. Evidence of efficacy within 30-90 days. A founder who embodies the ICP or built this for a loved one who did.

Once the product earns that positioning, the system works. Until then, you are pouring water into a leaking bucket.

Before you build a single email flow or test a single ad, you need to know the number.

Not your revenue target. Your subscriber target. And where those subscribers need to come from.

The UK is your proving ground, not your scale engine. Heights — one of the most well-known UK DTC supplement brands — hit 30,000 subscribers after five years of significant brand investment, a major podcast platform, and a high-profile first customer in Stephen Fry. For a specific health problem brand at a premium AOV, the realistic UK ceiling sits at 12-15,000 active subscribers.

That is not a pessimistic view. It is an honest one. And it is the number that makes the US expansion non-negotiable rather than aspirational.

At £65 per month — a defensible price point for a prescriptive, science-backed supplement — here is what the five-year journey looks like.

One correction before you read this table. The numbers below are net active subscribers — the subscribers still paying you at the end of each year. To hit these net figures, you need to acquire significantly more gross subscribers across the year because churn is constant. At a realistic 5-7% monthly churn rate for a well-run subscription supplement brand, you need to acquire roughly 35-40% more subscribers than your net target just to account for the subscribers you lose along the way. Year 1 net active of 5,000 requires approximately 6,500-7,000 gross acquisitions. That distinction matters for your capital map, which we address below.

The UK caps at 15,000 by year three. Everything after that comes from the US and selective international markets — Australia, Canada — where your category has proven demand and your DTC infrastructure translates without major reinvention.

The US is not a phase two ambition. It is the second half of the exit thesis.

A note on capital requirements. The subscriber math above implies a capital need that is higher than most founders anticipate. To hit 5,000 net active UK subscribers in Year 1 at £80 nCAC, you need approximately 6,500-7,000 gross acquisitions — around £520-560K in Meta spend alone across the year, concentrated in Q3 and Q4 once PMF is confirmed. Add product development, brand identity, inventory, and operational costs and the realistic Year 1 capital requirement sits at £700K-£1M, not the £250-500K figure commonly cited for DTC supplement launches. Plan for this from the start. Undercapitalising the acquisition phase is the single most common reason brands stall at 1,000-2,000 subscribers and never build the retention curve that makes the exit viable.

Before you spend a pound on acquisition, you need to understand what an acquirer sees when they look at your cohort data.

Strategic buyers and PE firms acquiring supplement brands are currently paying an average of 10.7x EV/EBITDA. That multiple is not applied to your revenue. It is applied to your EBITDA. And your EBITDA is a direct function of your retention curve.

Here is what acquisition-ready retention looks like across the four classes that DTC subscription data consistently produces:

Most founders assume they will be A Class. The data says they launch at C or D without knowing it.

M3 is the critical signal. It tells you whether a subscriber has formed a genuine habit or is still just a one-time buyer who set up a subscription for the convenience of the first order. If your M3 retention is below 40%, you are operating at C Class or below — and the acquisition math stops working.

The cohort half-life column shows you why. A D Class brand loses 50% of its cohort within 1.5 months. An A Class brand holds that cohort for 5.2 months. Every additional month of retention at scale is margin you do not have to spend acquiring a replacement subscriber.

The LTV efficiency column shows the real cost. A D Class brand captures 18.9% of the maximum LTV available from each cohort it acquires. An A Class brand captures 45.2%. Same product. Same price. Same Meta spend. The difference is the operating system behind the subscription — which is exactly what the phases below build.

For a strategic acquirer underwriting at 9-10x EBITDA, your retention class is the single most important input into their valuation model. They model years two, three, and four of revenue from your cohort data. B Class minimum to command a full multiple. A Class to command a premium.

The first phase of RULE OF ONE™ is the one most founders skip.

Before you spend a pound on acquisition, you need four numbers:

CM1 — your unit contribution margin after COGS and fulfilment. This tells you whether your product can be profitably shipped at your current price point.

CM2 — your contribution margin after variable marketing costs. This tells you whether your acquisition spend is sustainable at current conversion rates.

nCAC — your new customer acquisition cost, isolated from repeat buyers. Most brands calculate blended CAC, which flatters the number by mixing in organic and repeat purchasers. nCAC tells you the true cost of winning a new subscriber.

Payback period — how many days of subscription revenue it takes to recover your nCAC. Target: under 90 days. Under 60 is exceptional. Over 120 is a structural problem that no creative testing fixes.

These four numbers are your permission slip to scale. Without them, you are building on sand.

Subscription must be the default. Not an option. Not a save-and-subscribe toggle below the fold. The primary offer.

The pricing ladder runs: monthly subscription at the hero price point, quarterly prepay at a modest saving, six-month prepay at a stronger saving. Each longer commitment improves your EBITDA by reducing churn risk and improving cash flow predictability. Acquirers see longer average subscription lengths as a positive signal — it de-risks the revenue model.

One rule that most founders violate: never discount the subscription. Discount the one-time purchase to make the subscription feel like the obviously correct financial decision. The moment you put subscription pricing on sale, you erode the perceived premium of the model and train your audience to wait for offers.

Multibuy is your AOV lever. A 60-day or 90-day supply option, priced at a meaningful saving, raises your average order value without diluting the monthly subscription economics. Model every bundle against your contribution margin before it goes live.

Order one is the highest-leverage retention moment in your business.

Most founders treat it as fulfilment. The brands that hit 50%+ retention at month 12 treat it as clinical onboarding.

The packaging, the protocol card, the ritual object inside the box, the first post-purchase communication — all of it signals which psychological category this product lives in. Does it feel like a lifestyle purchase the customer might cancel when money gets tight? Or does it feel like a medical protocol they enrolled in?

Prescriptive brands engineer order one like a pharmaceutical company engineers a new patient intake.

The product arrives with a clear protocol. Day one through day 30. What to expect, when to expect it, why consistency matters, what happens if they miss a day. A QR code that deepens the relationship. A format — whether capsule, powder, drink — that is distinctive enough that the customer notices every time they reach for it.

The first email after purchase continues the onboarding. Not a receipt. Not a thank you. A welcome to a protocol.

If a customer completes week one with a clear understanding of what they are taking and why, their month-3 retention rate increases significantly. That moment of onboarding clarity is worth more than any discount or loyalty point you can offer.

Your landing page is not a brochure. It is a conversion instrument that tells you who your brand actually belongs to.

Run three ICPs simultaneously. Three landing pages. Three angles in Meta. The page that converts above 3% survives. Everything else is killed within 30 days.

Your ICPs are not demographics. They are psychographic states.

The person who has tried six supplements and found nothing that works. The high-performer who cannot afford cognitive decline at 45. The perimenopausal woman who has been told her symptoms are normal and has stopped believing that. The father who watched his own father suffer from the exact problem your product addresses.

Each one of these people needs a different opening line, a different proof point, and a different call to action.

Build a page for each. The winner tells you who your brand actually belongs to, what language converts, and which ICP is worth scaling into the US.

Years one and two: the founder IS the creative engine.

40-60% of your paid spend runs on founder-led content. Not polished brand advertising. Not UGC from micro-influencers. The founder, on camera, telling the truth about why they built this and what it does.

No actor carries the same credibility. No influencer carries the same conviction. The founder who built this product and uses it daily is the most powerful conversion asset in the business. In a market full of underdosed, overpromised supplements, authenticity is a structural advantage.

Test four angles relentlessly:

Problem. I had this specific health problem and it was affecting every area of my life. Here is what I tried. Here is what did not work. Here is what I eventually built.

Mechanism. Here is the specific biological or nutritional mechanism that makes this work when other approaches fail. Grounded in research. Explained simply.

Transformation. Here is what changed after 90 days of consistent use. Specific. Measurable. Believable.

Authority. Here is my background, my advisory team, and why I was qualified to build something different. The science behind the formula.

The angle that produces the lowest nCAC at a sustainable conversion rate becomes your ICP anchor. Micropersonas are built from that data. US expansion is seeded with the winning angle. Every new creative test is a variation on the proven thesis, not a departure from it.

Getting a subscriber is expensive. Keeping them through month 12 is how you build the business that commands a 9-10x EBITDA multiple.

Here is what the retention class means for your monthly Meta spend. At 5,000 active subscribers, a C Class brand losing 7% monthly needs to spend approximately £28,000 on Meta every month just to stay flat — before growing by a single subscriber. A B Class brand at 5% monthly churn spends £20,000 for the same outcome. That £8,000 monthly difference is £96,000 per year flowing directly to EBITDA. At a 9x exit multiple, it is worth £864,000 in exit value.

One percentage point of churn improvement is worth nearly £1M at exit. That is what this phase builds.

Three channels. One data source. Fully automated once built.

Email. The primary education and relationship channel. Order count is the trigger — not time. Behaviour drives the message, not the calendar.

SMS. Short. High-open rate. Used for renewal reminders, milestone recognition, and churn intervention. Not for long-form content.

Postcard. Physical mail at orders four, eight, and twelve. Not a discount voucher. A recognition moment. Handwritten-style note. Something that signals the brand noticed the subscriber is still here.

The education sequence runs in three phases:

Month 1-2: Educate. How the product works. What to expect in the first 30 days. Why consistency is the mechanism, not dosage. What changes to look for. This is where most brands stop communicating. It is where the retention work actually begins.

Month 3-4: Prove. Share transformation data from your subscriber base. Before and after testimonials. Third-party research. The science in plain language. This is the phase that carries subscribers through the danger zone — month three, where churn typically peaks.

Month 5 onwards: Identity lock-in. The subscriber is no longer someone who takes your supplement. They are someone who takes their health seriously. The brand's communication reflects that identity back to them. You are someone who does not skip this. This is who you are now.

The shift from product user to identity subscriber is when the retention curve flattens. That is the inflection point most brands never reach because they have already stopped communicating.

Churn intervention is triggered 72 hours before the expected cancellation window based on subscription platform data. Not a discount. A check-in. A reason to stay that is not financial.

This is the golden window.

The brands that install AI infrastructure into this operating system now will be three operational years ahead of those who wait until it feels necessary.

Where AI compounds the system:

Creative testing at scale. Fifty ad variants tested in the time it previously took to produce five. Winning angles identified faster. Losing angles killed sooner. The creative engine runs continuously without a bloated production team.

Retention personalisation. Dynamic email and SMS sequences triggered by individual subscriber behaviour — not just order count. A subscriber who opened every email about sleep but never clicked on energy content gets a different month-four message than one who did the opposite. That personalisation is now automated at scale.

ICP research. Audience intelligence that previously required a research agency now runs through a stack of AI tools in an afternoon. Comment mining, review analysis, Reddit and forum research — the ICP brief that took three weeks now takes three hours.

Overhead management. A founder with the right agent stack can run what previously required a ten-person team. That lower overhead is not just a cost saving. It is a direct EBITDA improvement. At exit, that cleaner cost structure is worth a higher multiple.

The brands building in 2026 with an AI-first operating model are doing in three years what took 2019-era brands eight. The window is open. It will not stay open indefinitely.

At £50M+ ARR with 20-22% EBITDA margins and a month-12 retention rate above 50%, a strategic acquirer will pay 9-10x EBITDA for your business.

That is a £90-110M exit.

At 40% founder ownership — achievable if you raise capital efficiently at the right stages and protect dilution in early rounds — your proceeds are £36-44M.

After UK capital gains tax, that is £27-33M in your pocket.

The operating system outlined here is not a nice-to-have. It is the infrastructure that makes that number real.

Every phase compounds the one before it. The financial diagnosis makes the offer architecture possible. The offer architecture makes the first purchase experience defensible. The first purchase experience makes the retention curve achievable. The retention curve makes the EBITDA real. The EBITDA makes the multiple justified.

Remove one phase and the system degrades. Run all seven and the outcome is predictable.

Everything outlined across the last two issues — the exit math, the product positioning, the subscriber roadmap, the retention infrastructure, the acquisition engine, the AI leverage layer — is the architecture I have built into a system called the RULE OF ONE™.

It is a seven-phase subscription operating system I install with CPG and wellness founders who are serious about building to exit with clean economics and real ownership intact.

If you are building a subscription-first supplement or wellness brand and you want to pressure-test your unit economics against this framework, start here.

Run your free subscription diagnostic → apply.consciouscommerceco.com/diagnose

If someone in your network is building a supplement or wellness brand and thinking seriously about the infrastructure behind a clean exit, forward this to them. The two-issue arc tells the full story.